Nu Skin: Patience Is Still Advised
Source: SeekingAlpha
2026-02-25 11:49:00 ET
Heading into an important year, there is a case on paper for Nu Skin Enterprises ( NUS ) stock. Shares are cheap, trading in the range of 3x adjusted EBITDA for 2026. Guidance for this year does seem to have disappointed, sending shares lower, but margins appear set to expand, and the company expects revenue growth to turn positive toward the tail end of the year....
Read the full article on Seeking Alpha
For further details see:
Nu Skin: Patience Is Still Advised
Nu Skin Enterprises Inc.
NASDAQ: NUS
NUS Trading
-0.98% G/L:
$7.10 Last:
111,274 Volume:
$7.19 Open:
NUS Latest News
February 13, 2026 09:43:00 am
Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NUS) 2025 Q4
February 12, 2026 04:06:00 pm
Nu Skin Enterprises Reports Fourth Quarter and Full-year 2025 Results Within Guidance
NUS Stock Data
$494,082,020
47,775,074
0.8%
61
N/A
Consumer Products - Healthcare
Consumer Staples
US
Provo
